コンテンツへスキップ
Merck

HT update: spotlight on estradiol/norethindrone acetate combination therapy.

Clinical interventions in aging (2008-05-21)
Colleen L Casey, Christine A Murray
要旨

Abstract: The goal ofpostmenopausal hormone therapy is to alleviate the symptoms that are associated with the loss of estrogen. Many formulations of estrogen and progestin are available, depending on the needs and circumstances of each individual woman. For postmenopausal women, the choice of whether or not to begin therapy requires knowledge of the risks and benefits of estrogen and/or progestin replacement. The purpose of this review is to describe the risks and benefits of hormonal therapy, focusing on estradiol/norethindrone acetate combination therapy.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
19-ノルエチンドロン, ≥98%, powder
USP
19-ノルエチンドロン, United States Pharmacopeia (USP) Reference Standard
19-ノルエチンドロン, European Pharmacopoeia (EP) Reference Standard